论文部分内容阅读
目的观察依达拉奉联合巴曲酶治疗急性脑梗死的疗效及安全性。方法95例急性脑梗死患者随机分为治疗组(49例)和对照组(46例),对照组应用巴曲酶和血塞通等治疗,观察组在对照组基础上加用依达拉奉,2周后两组患者进行临床疗效比较和血浆纤维蛋白原(Fg)含量变化的比较。结果治疗组显效率为69.4%,明显高于对照组显效率(47.8%),差异有统计学意义(P<0.01),两组Fg水平度较治疗前明显降低(均P<0.01)。结论依达拉奉联合巴曲酶治疗急性脑梗死患者,能显著提高疗效,降低患者Fg水平。
Objective To observe the efficacy and safety of edaravone and batroxobin in the treatment of acute cerebral infarction. Methods 95 patients with acute cerebral infarction were randomly divided into treatment group (n = 49) and control group (n = 46). The control group was treated with batroxobin and Xuesaitong. The observation group was treated with edaravone Two weeks later, the clinical efficacy and plasma fibrinogen (Fg) levels in two groups were compared. Results The effective rate of the treatment group was 69.4%, significantly higher than that of the control group (47.8%), the difference was statistically significant (P <0.01). The Fg level of both groups was significantly lower than that before treatment (all P <0.01). Conclusion Edaravone and batroxobin can significantly improve the curative effect and reduce the level of Fg in patients with acute cerebral infarction.